Advanced search
1 file | 118.00 KB Add to list

Maraviroc: integration of a new antiretroviral drug class into clinical practice

Linos Vandekerckhove (UGent) , Chris Verhofstede (UGent) and Dirk Vogelaers (UGent)
Author
Organization
Abstract
Maraviroc (Pfizer's UK-427857, Selzentry or Celsentri outside the US) is the first agent in the new class of oral HIV-1 entry inhibitors to acquire FDA and EMEA approval. It is expected that this drug will be effective only in a subpopulation of HIV-1-infected people, namely those harbouring only the R5 virus. The wide use of this drug is currently hampered by the lack of a readily available R5 virus only determination test (tropism test) and by insufficient scientific insight into the dynamics of R5 and X4 viruses during infection. We discuss the challenges associated with the currently available assay, as well as the potential role of alternative assays.
Keywords
co-receptor-blocker, V3 loop sequencing, tropism, chemokine receptor

Downloads

  • 1187.pdf
    • full text
    • |
    • open access
    • |
    • PDF
    • |
    • 118.00 KB

Citation

Please use this url to cite or link to this publication:

MLA
Vandekerckhove, Linos, et al. “Maraviroc: Integration of a New Antiretroviral Drug Class into Clinical Practice.” Journal of Antimicrobial Chemotherapy, vol. 61, no. 6, Oxford Univ. Press, 2008, pp. 1187–90, doi:10.1093/jac/dkn130.
APA
Vandekerckhove, L., Verhofstede, C., & Vogelaers, D. (2008). Maraviroc: integration of a new antiretroviral drug class into clinical practice. Journal of Antimicrobial Chemotherapy, 61(6), 1187–1190. https://doi.org/10.1093/jac/dkn130
Chicago author-date
Vandekerckhove, Linos, Chris Verhofstede, and Dirk Vogelaers. 2008. “Maraviroc: Integration of a New Antiretroviral Drug Class into Clinical Practice.” Journal of Antimicrobial Chemotherapy 61 (6): 1187–90. https://doi.org/10.1093/jac/dkn130.
Chicago author-date (all authors)
Vandekerckhove, Linos, Chris Verhofstede, and Dirk Vogelaers. 2008. “Maraviroc: Integration of a New Antiretroviral Drug Class into Clinical Practice.” Journal of Antimicrobial Chemotherapy 61 (6): 1187–1190. doi:10.1093/jac/dkn130.
Vancouver
1.
Vandekerckhove L, Verhofstede C, Vogelaers D. Maraviroc: integration of a new antiretroviral drug class into clinical practice. Journal of Antimicrobial Chemotherapy. 2008;61(6):1187–90.
IEEE
[1]
L. Vandekerckhove, C. Verhofstede, and D. Vogelaers, “Maraviroc: integration of a new antiretroviral drug class into clinical practice,” Journal of Antimicrobial Chemotherapy, vol. 61, no. 6, pp. 1187–1190, 2008.
@article{601735,
  abstract     = {{Maraviroc (Pfizer's UK-427857, Selzentry or Celsentri outside the US) is the first agent in the new class of oral HIV-1 entry inhibitors to acquire FDA and EMEA approval. It is expected that this drug will be effective only in a subpopulation of HIV-1-infected people, namely those harbouring only the R5 virus. The wide use of this drug is currently hampered by the lack of a readily available R5 virus only determination test (tropism test) and by insufficient scientific insight into the dynamics of R5 and X4 viruses during infection. We discuss the challenges associated with the currently available assay, as well as the potential role of alternative assays.}},
  author       = {{Vandekerckhove, Linos and Verhofstede, Chris and Vogelaers, Dirk}},
  issn         = {{0305-7453}},
  journal      = {{Journal of Antimicrobial Chemotherapy}},
  keywords     = {{co-receptor-blocker,V3 loop sequencing,tropism,chemokine receptor}},
  language     = {{eng}},
  number       = {{6}},
  pages        = {{1187--1190}},
  publisher    = {{Oxford Univ. Press}},
  title        = {{Maraviroc: integration of a new antiretroviral drug class into clinical practice}},
  url          = {{http://doi.org/10.1093/jac/dkn130}},
  volume       = {{61}},
  year         = {{2008}},
}

Altmetric
View in Altmetric
Web of Science
Times cited: